Purpose Biodegradable polylactic-co-glycolic acid (PLGA) nanoparticles can adsorb at the water/oil interface to stabilize the emulsion (forming Pickering-emulsion). The purpose of this study was to compare the release profiles of oxaliplatin from Pickering-emulsion and Lipiodol-emulsion. Materials/Methods Pickering-emulsions and Lipiodolemulsions were both formulated with oxaliplatin (5 mg/ mL) and Lipiodol (water/oil ratio: 1/3). For Pickeringemulsion only, PLGA nanoparticles (15 mg/mL) were dissolved into oxaliplatin before formulation. In vitro release of oxaliplatin from both emulsions was evaluated. Then, oxaliplatin was selectively injected into left hepatic arteries of 18 rabbits bearing VX2 liver tumors using either 0.5 mL Pickering-emulsion (n = 10) or 0.5 mL Lipiodolemulsion (n = 8). In each group, half of the rabbits were killed at 1 h and half at 24 h. Mass spectrometry was used to quantify drug pharmacokinetics in blood and resulting tissue (tumors, right, and left livers) oxaliplatin concentrations.
Introduction
Drug delivery platforms are currently used during liver transarterial chemoembolization (TACE) procedures. These act as a transient reservoir, allowing slow release of the chemotherapy into the tumors' supply to achieve a prolonged exposure of the tumor cells while minimizing systemic exposures. In clinical practice, Lipiodol and drugeluding microspheres are the two most widely used drug delivery platforms for TACE. Both platforms have been used for the treatment of hepatocellular carcinoma [1] and liver metastases from neuroendocrine or colorectal cancers.
Lipiodol (Guerbet, Aulnay-sous-Bois, France) is an oilybased radio-opaque contrast agent that also serves as a drug delivery platform because of its radio-opacity and its preferential tumor uptake compared to surrounding liver tissue [2] . Since most anticancer drugs are water soluble, the vectorization mechanism consists in formulating a water-in-oil emulsion between the chemotherapy (aqueous phase) and the Lipiodol (oily phase) [3] . However, the release of chemotherapy occurs very rapidly because Conventional-emulsions have relatively poor stability. Within a few minutes, the two phases of the emulsion separate with bulk of the water-soluble chemotherapy releasing rapidly from the Lipiodol resulting in high systemic exposures to the chemotherapy and diminished deposition of the chemotherapy into the targeted tumor tissues [4] .
Drug-eluding microspheres are polyvinyl alcohol-based hydrogel microspheres that can be loaded with chemotherapy and used for TACE [5] . The presence of the anionic sulphonate group enables the sequestering of positively charged drugs only (Coulomb charge interactions). Thus, doxorubicin, epirubicin, or irinotecan are the only chemotherapies that can be readily used in clinical practice. In addition, because of variable ionic interaction intensity between microspheres and the chemotherapy, the release could be either incomplete and very slow (doxorubicin) or complete and very fast (irinotecan) [6] . Finally, the microspheres are not only a drug delivery platform but also an embolic medical device (different sizes available, ranging from 40 up to 700 lm) that block the arterial flow. This property helps to increase the tumor drug exposure but can also induce hypoxia and the associated unwanted development of new tumor blood vessels (tumor neo-angiogenesis) [7] .
We have developed a new concept for a drug delivery platform that allows a slow and controlled release of various types of chemotherapies while maintaining the added value of Lipiodol in terms of a radio-opacity, preferential tumor uptake [8] , and transient vessels' occlusion [9] . The principle is based on Pickering technology [10, 11] that uses solid particles to stabilize emulsions. The use of solid particles (Pickering technology) in the formulation of an emulsion avoids the use of toxic synthetic surfactants and results in very stable interfaces between the aqueous phase and the oily phase. The absence of synthetic surfactant makes Pickering-emulsion very attractive, especially for biomedical applications.
Oxaliplatin was the chosen chemotherapy in this study for two main reasons. First, several studies have already demonstrated that transarterial injection of platinum-based chemotherapy is effective in the treatment of unresectable liver tumors such as colorectal metastases [12, 13] and hepatocellular carcinoma [14, 15] . Second, few studies report the use of oxaliplatin-eluding microspheres in animal models [16] and in a preliminary human study published in 2008 [17] , but in clinical routine, no drug delivery platform for platinum-based chemotherapy can be used so far. Indeed, platinum-based chemotherapies cannot be loaded in drug-eluding microspheres since these chemotherapies are not positively charged. The use of Lipiodol is also problematic since the absence of powder form for platinum-based chemotherapies makes the reconstitution with contrast media impossible, resulting in very unstable emulsion. The purpose of this study was to compare the release profiles of oxaliplatin from Pickeringemulsion and Conventional-emulsion in both in vitro and in vivo settings.
Materials/Methods
This study has two successive stages to compare Pickeringemulsion and Conventional-emulsion. The first stage was designed to compare the in vitro release profile of oxaliplatin from the two emulsions. The second stage used the VX2 rabbit liver tumor model to compare the plasmatic pharmacokinetics of oxaliplatin and tissue exposures upon release from the two emulsions.
Formulation of the Lipiodol-Emulsions
Two different types of water-in-oil Lipiodol-emulsions were formulated: Conventional-emulsion and Pickeringemulsion.
For both emulsions, the oily phase was composed of Lipiodol and the aqueous phase was composed of oxaliplatin (5 mg/mL). Polylactic-co-glycolic acid (PLGA) nanoparticles were added to the aqueous phase during formulation of the Pickering-emulsion; latter component was the only difference between the 2 emulsions (15 mg of PLGA nanoparticles per mL of oxaliplatin). These PLGA nanoparticles are biodegradable [18] and adsorb at the water/oil interface to stabilize the Lipiodol-emulsion (Fig. 1) . Water-in-oil Lipiodol-emulsions were formulated by continuous injection of 1 volume of aqueous phase in 3 volumes of oily phase with an electric syringe pump (flowrate of 1 mL per minute) during repetitive pumping of two 10-mL syringes through a three-way stopcock [19] .
In Vitro Stage
In vitro release of oxaliplatin from the two emulsions was evaluated. We performed the experiments twice for each Lipiodol-emulsion: An aliquot of 0.8 mL of emulsion was loaded into mini GeBAflex tubes (molecular weight cutoff: 12-14 kDa; Gene Bio-Application Ltd., Kfar Hanagide, Israel). These tubes were immersed in 40 ml of buffer solution (acetate buffer 25 mM, pH 6.8) and incubated in a shaking bath (37°C) rotated at a speed of 150 rpm for the entire period. At predetermined times (1, 4, 24, 48, 72 h, 1, 2 weeks, and 1 month), 0.5 mL of buffer solution was collected for oxaliplatin quantification.
Animal Stage
This stage was performed in accordance with our Institutional Animal Care and Use Committee guidelines. VX2 liver tumors were percutaneously implanted in New Zealand white rabbits under general anesthesia (Intramuscular injections of Ketamine 20-40 mg/kg and xylazine 3-5 mg/ kg, Isoflurane 3-5% for induction and 1.5-3% for maintenance mixed with O 2 at 1 L/min). For this purpose, 1-2 mm freshly harvested tumor fragments, coming from the hind limb tumors of donor rabbits were implanted under ultrasound guidance through a 18G needle positioned at 3 different locations of the left liver. One week after the liver tumor implantations, MR checkup scans were performed to confirm tumor growth and locations within the liver.
Two weeks after liver tumor implantations, TACE procedures were performed by an experienced interventional radiologist (FD), under general anesthesia and fluoroscopic guidance (OEC 9800 Plus Mobile C-arm, Milwaukee, Wisconsin, USA). The femoral artery was surgically exposed and catheterized with a 4F vascular sheath using Seldinger approach. A micro-catheter (2.4F Merit Maestro Merit medical Ò , South Jordan, UT, USA) was used to selectively engage the left hepatic artery (Fig. 2) and to inject 0.5 mL of emulsion corresponding to 0.625 mg of oxaliplatin. Attention was given to avoid any reflux into the right hepatic artery, and additional embolization with gelatin sponge was considered only in cases of persistent flow in the left hepatic artery after completion of the emulsion injection.
Heparinized systemic blood samples (2 mL) were collected from the vascular sheath 5, 10, 20, 30, and 60 min after the injection of the emulsion to measure the plasmatic pharmacokinetics of oxaliplatin. The procedures were either non-recovery procedures (killing at 1 h, immediately after the last blood sample collection) or recovery procedures with killing at 24 h. Four different groups of rabbits were considered according to the type of emulsion each received and according to the delay before killing:
Group-1: rabbits received Conventional-emulsion and were killed 1 h after the injection. Group-2: rabbits received Pickering-emulsion and were killed 1 h after the injection. Group-3: rabbits received Conventional-emulsion and were killed 24 h after the injection. Group-4: rabbits received Pickering-emulsion and were killed 24 h after the injection.
Immediately after killing, post-TACE MR scan (3T Magnetom Skyra; Siemens, Erlangen, Germany), using a 15 channels knee coil, was performed for each rabbit to measure and enumerate the liver tumors (Fig. 2) . Next, livers were resected. Tissue samples from the right and left livers, as well as all the tumors, were dissected separately and homogenized with a blender for oxaliplatin quantification. Since the right liver was not injected during TACE, the quantification of oxaliplatin in this tissue was used to evaluate the systemic exposure of the chemotherapy after TACE.
Oxaliplatin Quantification
Quantification of oxaliplatin was accomplished using inductively coupled plasma mass spectrometry (ICP-MS) of acid-digested samples. Specifically, blood and tissue samples were digested in concentrated trace nitric acid ([ 69%, Thermo Fisher Scientific, Waltham, MA, USA) and placed at 60°C for 24 h to allow for complete sample digestion. Ultrapure H 2 O (18.2 MX cm) was then added to produce a final solution of 3.0% nitric acid and 4.0% hydrochloric acid in a total sample volume of 5 mL. 
Platinum quantification served as our assay for oxaliplatin drug concentration (1 mg of oxaliplatin corresponds to 0.49 mg of platinum). Quantitative standards were made using individual 1000 lg/mL platinum elemental standards (Inorganic Ventures, Christiansburg, VA, USA), which were combined to create a 100 ng/mL mixed element standard in 2.0% nitric acid and 4.0% hydrochloric acid (v/ v) in a total sample volume of 50 mL. ICP-MS was performed on a computer-controlled (QTEGRA software) Thermo iCapQ ICP-MS (Thermo Fisher Scientific, Waltham, MA, USA) operating in STD mode and equipped with an ESI SC-2DX prepFAST autosampler (Omaha, NE, USA). Internal standard was added inline using the prep-FAST system. Online dilution was also carried out with the prepFAST system to generate calibration curves consisting of 100, 50, 20, 10, 5, 2, 1 ng/mL platinum. Each sample was acquired using 1 survey run (10 sweeps) and 3 main (peak jumping) runs (40 sweeps).
Statistical Analysis
Data were presented as the mean value ± SD. MannWitney test was used assess differences between means (ttest). P \ 0.05 was considered statistically significant.
Results

In Vitro Stage
The oxaliplatin release profiles of the two different emulsions are shown in Fig. 3 . Conventional-emulsion demonstrated a rapid drug release compared with Pickeringemulsion. The percentage of oxaliplatin released from Conventional-emulsions and Pickering-emulsions were respectively: 12.0 ± 6 vs. 1.5 ± 0.2% at 1 h, 50.0 ± 13.8 vs. 4.7 ± 0.9% at 4 h, 85.3 ± 3.3 vs. 15.8 ± 3.0% at 24 h. The release of oxaliplatin from the Conventional-emulsions was nearly complete within 24 h whereas release was still ongoing from the Pickering-emulsions after 1 month (72.0 ± 2.1%).
Animal Stage
A total of 18 rabbits (3.5 ± 0.3 kG) bearing a total of 33 VX2 liver tumors (1-3 tumor(s)/rabbit) received selective left hepatic artery injection of 0.5 mL emulsion. No additional embolization with gelfoam was performed since forward flow was already completely stopped by the emulsion. Nine rabbits were killed at 1 h, and 9 rabbits were killed at 24 h. Four rabbits bearing 6 tumors were included in Group-1, 5 rabbits bearing 9 tumors in Group- 2, 4 rabbits bearing 9 tumors in Group-3, and 5 rabbits bearing 9 tumors in Group-4. The maximal tumor diameter was 15.0 ± 6.4 mm without any statistically significant difference between the 4 groups.
Plasmatic Pharmacokinetics of Oxaliplatin
Plasmatic pharmacokinetics of oxaliplatin after injection of the two emulsions are shown in Table 1 and Fig. 4 . We observed a significantly lower peak oxaliplatin concentration in the blood (C max ) after injection of Pickeringemulsion (0.49 ± 0.14 ng/mL) compared to Conventionalemulsion (1.08 ± 0.41 ng/mL, p \ 0.01). The AUC at 1 h was significantly lower for the Pickering-emulsion (19.8 ± 5.9 vs. 31.8 ± 14.9, p = 0.03).
Oxaliplatin Concentration in Liver and Tumor Tissues
Oxaliplatin concentrations in tissues (tumors, right, and left livers) are, respectively, presented Table 1 and in Table 2 . At 24 h, the oxaliplatin concentration ratio between tumor and the left liver was significantly higher with Pickering-emulsion compared to Conventional-emulsion (43.4 ± 42.9 vs. 14.5 ± 6.6, p = 0.04), and there was a trend of significance for higher ratio between the oxaliplatin concentrations in tumors and right liver at 24 h in favor of Pickering-emulsion compared to Conventionalemulsion (45.6 ± 38.5 vs. 18.6 ± 17.5 ng/mg, p = 0.06).
Discussion
The term ''water-in-oil emulsion'' refers to fine droplet dispersions of an aqueous phase in a continuous oily phase. The high interfacial energy of the dispersed droplets in the oily phase contributes to thermodynamic instability and results in a coalescence process when droplets bump into each other and combine to form a larger droplet, so the average droplet size increases over time. However, a stable Lipiodol-emulsion is critical for TACE, allowing slow release of the chemotherapeutic agent into the liver tumor feeders for prolonged exposure, while minimizing systemic exposure [20] [21] [22] . Stable emulsions can be obtained using substances known as emulsifiers that are able to decrease the interfacial tension between the two phases. Emulsifiers are commonly included in emulsion formulations. Synthetic surfactants have been used to stabilize emulsions made of Lipiodol and chemotherapy [20] . However, these surfactants can raise toxicity issues, either directly or indirectly. Alternatively, the Pickering-emulsion uses solid particles as emulsifiers. The adsorption of the solid particles at the water/oil interface leads to the formation of a protective film that resists droplet coalescence and phase separation. The biodegradability of PLGA nanoparticles and the high stability of Pickering-emulsions lend unique properties when compared against classical emulsions stabilized by synthetic surfactants and make them very attractive for biomedical applications such as TACE.
We demonstrated that the use of PLGA nanoparticles in the formulation of an emulsion of Lipiodol and oxaliplatin results in a slower release of oxaliplatin in vitro. Indeed, the release of oxaliplatin from a Conventional-emulsion was almost complete within 24 h whereas only 15% of the oxaliplatin was released within 24 h when nanoparticles were added into the aqueous phase. Based on our in vitro study, we can also see that after 1 month, the total release of oxaliplatin from the Pickering-emulsion was roughly 72%. This slow release results in significant decrease of the plasmatic peak and of the area under the curve in vivo. The significantly higher concentrations of oxaliplatin in tumors and left livers with Conventional-emulsion at 1 h are consistent with the poor stability of the emulsion that Oxaliplatin is a valid option for chemotherapy for patients suffering from HCC [14, 15] and colorectal cancer liver metastases [12, 13] . In colorectal cancer, oxaliplatin is a pillar of many systemic regimens in combination with 5-FU. Moreover, the drug has been used through hepatic arterial infusion (HAI), and its association with systemic chemotherapy has demonstrated very overall response rate in second or more advanced line of IV chemotherapy [23] and even in patients who have progressed on IV oxaliplatin [24] . In rabbit VX2 liver tumor models [25] , HAI of oxaliplatin has demonstrated a tumor versus healthy hepatic tissue ratio of 4.3 at 24 h. Our study reports a ratio at 24 h of 44.1 for Pickering-emulsions and 11.8 for Conventional-emulsions, clearly suggesting the potential benefit of using a drug delivery platform for the arterial delivery of oxaliplatin in order to potentiate tumor response and reduce systemic toxicities.
We acknowledge some limitations to the current study. The first one was that we considered Conventional-emulsion as a gold standard for evaluating the release of oxaliplatin from Pickering-emulsions. However, there is no other drug delivery system that we could have used for comparison since oxaliplatin cannot be loaded onto clinically approved drug-eluding bead platforms. A high ratio of Lipiodol/oxaliplatin (3/1) and continuous and slow incorporation of oxaliplatin in the Lipiodol were considered in order to obtain the best stability of the Lipiodolemulsion [3, 19, 26] . Another limitation was that we decided to early kill the rabbits in order to demonstrate a pharmacokinetic advantage within the first 24 h. Since oxaliplatin slowly released from Pickering emulsion, additional animals must be done to evaluate histological findings (necrosis) and tumor response. Another limitation was that no embolic agent was injected during the TACE procedures (as would commonly be performed for clinical TACE studies). However, hepatic artery antegrade flow was completely stopped at the conclusion of each emulsion injection thus additional embolization would have suboptimally resulted in retrograde-flow within extra-hepatic arteries in our rabbit model. Additional embolizations would also introduce biases during the evaluation of oxaliplatin release from the emulsions. Finally, additional studies must be done to further evaluate the biocompatibility of the PLGA nanoparticles that we used in this study.
We believe that this experimental study may offer potential implication for patient care. First, new chemotherapies, such as oxaliplatin, can be stabilized in Lipiodol-emulsion thanks to the use of nanoparticles, offering new perspectives for liver TACE. The second point of interest is that the use of nanoparticles significantly decreases systemic oxaliplatin exposure and increases the tumor oxaliplatin concentration selectivity at 24 h. This could lower systemic toxicities after Lipiodol TACE and potentially increase tumor response in liver cancer patients.
